EWING, NJ--(Marketwire - December 01, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or the “Company”) announced today that it has received $1.5 million under a letter of intent with Sigma-Tau Pharmaceuticals, Inc. (“Sigma-Tau”), which grants Sigma-Tau an exclusive right to negotiate terms and conditions for a possible business transaction or strategic alliance regarding orBec® (oral beclomethasone dipropionate or oral BDP) and potentially other DOR pipeline compounds until March 1, 2009.
